Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
Status:
Completed
Trial end date:
2016-10-30
Target enrollment:
Participant gender:
Summary
This is a single arm, one center, phaseⅡ study evaluating efficacy and safety of erlotinib as
neoadjuvent treatment in patients with EBUS confirmed stage ⅢA N2 NSCLC with activating EGFR
mutation in exon 19 or 21.